Danaher Corporation Stock Price, News & Analysis

Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will present at the Wolfe Research Healthcare Conference on November 19, 2020, at 12:00 p.m. ET. The presentation will be available via simultaneous webcast on the Danaher website.

As a global innovator in science and technology, Danaher operates in healthcare, environmental, and applied markets, employing over 67,000 associates. For more information, visit www.danaher.com.

Beckman Coulter has launched its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in CE Mark countries. The test exhibits 99.9% specificity and 98.3% sensitivity 15-30 days post-symptom onset, offering a positive predictive value of 95.5% in populations with a 3% disease incidence. This assay complements Beckman Coulter's suite of COVID-19 testing solutions, which include IgG assays and an antigen test under development. Beckman Coulter aims to address high testing demands by leveraging its advanced automation technology, capable of delivering over 15 million tests monthly.

Cytiva has launched new services aimed at supporting point-of-care diagnostic developers, enhancing speed to market for new tests. The initiative includes establishing new labs in Germany and China, and expanding existing facilities in Wales. A multi-million dollar investment will boost diagnostic capabilities and supply chain enhancements. Cytiva has played a pivotal role during the COVID-19 pandemic, aiding the testing of over 50 million individuals. This investment is part of a broader $500 million plan to expand manufacturing capacity over five years.

Danaher Corporation (NYSE: DHR) reported strong financial results for Q3 2020, with net earnings of $883.5 million ($1.16 per diluted share), up 38% year-over-year. Non-GAAP adjusted earnings per share increased by 62% to $1.72. Revenues rose 34.5% to $5.9 billion, with core revenue growth at 14%. Operating cash flow surged 93% to $1.7 billion, and free cash flow increased by 110% to $1.5 billion. The company anticipates low-double digit revenue growth for Q4 2020, emphasizing its resilience and commitment to addressing COVID-19 challenges.

Beckman Coulter announced on Oct. 15, 2020, that it received funding from the Biomedical Advanced Research and Development Authority (BARDA) for a multi-center clinical trial validating the Monocyte Distribution Width (MDW) biomarker. This biomarker aids in the rapid detection of Multisystem Inflammatory Syndrome in Children (MIS-C), a severe complication of COVID-19. The funding will support collaboration with Massachusetts General Hospital, Johns Hopkins University, and the University of Florida.

Beckman Coulter announced that its Access SARS-CoV-2 Immunoglobulin M (IgM) assay has received Emergency Use Authorization (EUA) from the U.S. FDA. The assay detects IgM antibodies with 99.9% specificity and 98.3% sensitivity, aiding in COVID-19 diagnostics. This product is part of a broader suite of COVID-19 testing solutions, which includes the previously authorized IgG assay and an IL-6 assay for severe inflammatory responses. Beckman Coulter is also developing a SARS-CoV-2 antigen assay and a quantitative IgG assay, showing its commitment to advancing healthcare.

Danaher Corporation (NYSE: DHR) will host a webcast of its third quarter 2020 earnings conference call on October 22, 2020, at 8:00 a.m. ET, lasting approximately one hour. The call can be accessed via Danaher's website under the 'Investors' section. A replay will be available after the call until November 5, 2020. The earnings press release, along with related materials, will be posted at 6:00 a.m. ET on the call date. Danaher focuses on innovative science and technology solutions in healthcare and environmental sectors.

On October 6, 2020, Danaher Corporation (NYSE:DHR) announced the redemption of all €800,000,000 1.700% Senior Notes due 2022. The redemption will occur on November 5, 2020, at a price equal to the principal amount plus a make-whole premium and accrued interest. Funding for this redemption will come from the proceeds of a recent senior notes offering. Danaher continues to focus on innovation across healthcare and environmental markets with over 67,000 associates globally.